Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 2 Completed 23 enrolled Mateon Therapeutics

Non-randomizedParallel-groupDouble-blindTreatment

Summary

The objectives of this study are to evaluate the safety and efficacy of 3 dose groups (27, 36 and 45 mg/m2) of Combretastatin A-4 Phosphate for the treatment of subfoveal choroidal neovascularization in subjects with pathologic myopia.

Timeline

Start: 2005-03
Primary completion: 2007-01
Completion: 2007-01

Publications

Giri P, Batra PJ, Kumari A, Hura N, Adhikary R, Acharya A, Guchhait SK, Panda D. Development of QTMP: A promising anticancer agent through NP-Privileged Motif-Driven structural modulation. Bioorg Med Chem. 2023 Nov 15;95:117489. doi: 10.1016/j.bmc.2023.117489. Epub 2023 Oct 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	fosbretabulin	Small molecule	27 mg/m2	—
Subject	fosbretabulin	Small molecule	36 mg/m2	—
Subject	fosbretabulin	Small molecule	45 mg/m2	—

Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Summary

Timeline

Publications

Drugs

Indications